fashion -WSS

fashion

author：leisure time 2025-09-02 11:43:53 - browse：244

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

WSS

Diagnostic tests are hitting their mathematical limits

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

How to pay for weight loss drugs and save Medicare

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

BIO selects John Crowley as new CEO

Mike Pence clashes with Tucker Carlson in Iowa

explore

fashion

focus

Hepatitis C has a cure — but many Americans still lack access to it

Does aspartame cause cancer? What new WHO guidance says

23andMe had bad news about my health. I wish a person had delivered it

Diagnostic tests are hitting their mathematical limits

Affirmative action in medical school literally saved lives

What don’t we know about an Alzheimer’s drug side effect?

Medicare details structure of new drug price negotiation program

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Trump demands the U.S. pay no more for drugs than other countries … again

Argenx drug significantly slows progression of nerve disorder

leisure time

The new HIV moral panic

As biotech industry slumps, bioscience job market is upside down

Pediatric cancer treatments threatened by a new FDA policy

Congress likely to miss an opportunity to fix drug shortages issue

Georgia court denies Trump's request to quash DA's 2020 election probe

Grail faces three suits alleging harassment, retaliation

knowledge

focus

Wikipedia

focus